SCHEMBL1692091

SCHEMBL1692091

CCOC(=O)N1CC2CCCC(O)C2C1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 6/20 0.44
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
THRB P10828 1/20 0.41
ATM Q13315 1/20 0.41
GAA P10253 2/20 0.41
TSHR P16473 2/20 0.40
MAPT P10636 1/20 0.38
CHRM5 P08912 1/20 0.38
CYP1A2 P05177 1/20 0.38
VNN1 O95497 1/20 0.38
HTT P42858 1/20 0.38
RECQL P46063 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6674242 0.81 CHRM1 (0.55) CHRM1ALDH1A1L3MBTL1THRBATM
SCHEMBL6674245 0.81 CHRM1 (0.55) CHRM1ALDH1A1L3MBTL1THRBATM
SCHEMBL6679686 0.81 CHRM1 (0.55) CHRM1ALDH1A1L3MBTL1THRBATM
SCHEMBL19779324 0.80 NR1H2 (0.50) CHRM1ALDH1A1MAPTRECQLMEN1
SCHEMBL21480200 0.80 NR1H2 (0.50) CHRM1ALDH1A1MAPTRECQLMEN1
SCHEMBL19779325 0.80 NR1H2 (0.50) CHRM1ALDH1A1MAPTRECQLMEN1
SCHEMBL13698916 0.77 CHRM1 (0.51) CHRM1ALDH1A1L3MBTL1THRBATM
SCHEMBL21460094 0.76 VNN1 (0.39) VNN1
SCHEMBL21159381 0.74 NR1H2 (0.47) CHRM1ALDH1A1L3MBTL1THRBATM
SCHEMBL21138276 0.74 NR1H2 (0.47) CHRM1ALDH1A1L3MBTL1THRBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130331568-A1 ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY NOVARTIS AG (CH) 2013-12-12 US disclosed
US-8536229-B2 Acetylene derivatives having MGluR 5 antagonistic activity NOVARTIS AG (CH) 2013-09-17 US disclosed
US-20120010263-A1 ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY NOVARTIS AG (CH) 2012-01-12 US disclosed
US-20080146647-A1 ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY NOVARTIS AG (CH) 2008-06-19 US disclosed
US-7348353-B2 Acetylene derivatives having mGluR 5 antagonistic activity NOVARTIS AG (CH) 2008-03-25 US disclosed
EP-1453512-B8 ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY NOVARTIS AG (CH) 2006-07-19 EP disclosed
EP-1453512-B1 ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY NOVARTIS AG (CH) 2006-05-31 EP disclosed
US-20050065191-A1 Acetylene derivatives having mglur 5 antagonistic activity NOVARTIS AG (CH) 2005-03-24 US disclosed
EP-1453512-A1 ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY Novartis AG (CH) 2004-09-08 EP disclosed
WO-2003047581-A1 ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY NOVARTIS AG (CH) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331568-A1 ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY GRM5, GRM1, GRIK5 CHRM1 114/4885ALDH1A1 1423/4885L3MBTL1 3558/4885
US-20080146647-A1 ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY GRM5, GRIK5, GRM1 CHRM1 243/4885ALDH1A1 1400/4885L3MBTL1 4416/4885
US-20050065191-A1 Acetylene derivatives having mglur 5 antagonistic activity GRM5, GRM1, GRM2 CHRM1 68/4885ALDH1A1 1205/4885L3MBTL1 2889/4885
US-20120010263-A1 ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY GRM5, GRIK5, GRM1 CHRM1 243/4885ALDH1A1 1400/4885L3MBTL1 4416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.